
Opinion|Videos|October 23, 2023
Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations
Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discuss the importance of early dermatological consultations and multidisciplinary education for managing infusion-related adverse events like rashes from amivantamab, emphasizing the benefits of a well-coordinated team and the value of experience in responding to reactions.
Advertisement
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Spotlighting the Top 10 FDA Oncology Approvals in 2025
2
A Look Back on the Top 10 Oncology Interviews in 2025
3
Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer
4
‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer
5













